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The part that antithrombin plays in the human blood in inhibiting 
coagulation is a  question concerning which there is a  decided differ- 
ence of opinion.  Although it is admitted generally by physiologists 
that  antithrombin  is  present  in  the  circulating  blood,  there  is  a 
marked  divergence  as  to  the  significance  and  importance  which 
should be  accorded  it.  On  the one hand,  we note that  Morawitz, 
whose theory of coagulation has  gained wide acceptance,  assigns  to 
antithrombin no function in the theory of coagulation which he has 
elaborated.  This  omission  seems  to  be  a  weak  link  in  the  chain 
which  he  has  constructed,  as  any  theory  is  necessarily  incomplete 
which  leaves  out  of  consideration  a  substance  which  is  regularly 
present  in  the  circulating blood.  On  the  other  hand,  Howell  con- 
siders antithrombin to be a  very important constituent,  ascribing to 
it the part of maintaining the fluidity of the blood,  in that coagula- 
tion  ensues  only  when  the  antithrombin  is  rendered  inert  by  the 
neutralizing effect of the zymoplastic substance in the shed blood or 
in the tissues.  As stated, however, there is no diversity of opinion 
regarding the normal  occurrence of antithrombin,  so that  it  would 
seem worth while to study this substance clinically from a  quantita- 
tive point of view, in order to obtain fuller data from which to judge 
its importance.  The term antithrombin is employed in a  functional 
sense to designate  any substance or substances  in the plasma which 
tend to inhibit coagulation.  It is realized that a  terminology, of this 
kind  cannot  be  absolutely  satisfactory,  especially  from  a  chemical 
point of view.  Nevertheless,  it  appears  to be justifiable;  it  is,  for 
example,  in accordance  with the physiological studies  in  immunity, 
where  all  the  substances,--complement,  amboceptor,  etc.,--exist 
only from a  functional viewpoint. 
There have been very few quantitative examinations of antithrom- 
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bin in the human blood.  This, probably, may be  accounted for by 
the fact that it has been overshadowed by the striking importance of 
other substances in the btood,--the thrombin, fibrinogen, and other 
active principles, which may be grouped as the positive coagulative 
factors,--and  in  part  by  the  fact  that  there  has  been  no  simple 
method for making such tests.  The few estimations of this nature 
which have been carried out have been reported by Howell, who used 
a  method which he has devised.  Although this method seems to be 
satisfactory,  it is by no means simple, and  is hardly suited to wide 
clinical use.  In the first place, it requires the preparation of a  pure 
thrombin.  This is extracted  from pig fibrin by treating it with an 
8 per cent. solution of sodium chloride, followed by repeated extrac- 
tions of the coagulable proteins by means of chloroform.  The test 
also requires the preparation of a  solution of fibrinogen which must 
contair/  no  prothrombin;  that  is,  must  not  clot  merely  upon  the 
addition'of calcium.  It requires considerable experience to prepare 
both of these substances satisfactorily; the fibrinogen solution, which 
is not the salted fibrinogen of Hammarsten, but a  dialyzed plasma, 
is especially difficult to obtain and to maintain free from contamina- 
tion of prothrombin. 
In  the  course  of  testing  the  coagulability  of  oxalated  plasma 
from  various  sources,  an  examination  which  included  a  test  for 
antithrombin,  it  was  found  that  for  clinical  use  a  simple  method 
could be employed, which requires neither a preparation of thrombin 
nor of fibrinogen.  The method is carried out as follows : 
About nine cubic centimeters of blood are aspirated and put into 
one cubic centimeter of  I  per  cent.  sodium oxalate.  The blood  is 
centrifugalized  and  the  plasma  removed  in  the  usual  way.  The 
plasma is then recalcified by adding 2, 3, 4, and 5 drops, respectively,. 
of a  o. 5 per cent. calcium chloride solution.  In this way we ascer- 
tain the general coagulability of the plasma, which is the composite 
of a  number of interacting factors,--prothrombin,  fibrinogen, anti- 
thrombin,  etc.mand  we  determine  at  the  same  time  the  optimalJ 
amount of calcium for this particular plasma. 
If we heat some of this plasma to 6o °  C.,  the prothrombin, as is 
well known,  is  destroyed and  the  fibrinogen  is  coagulated.  After 
filtering  off  the  coagulum we  have  a  plasma  which' contains  anti- 840  Test for Antithrombin  in the Blood. 
thrombin and practically no prothrombin.  The strength of this anti- 
thrombin  may  be ascertained,  for  clinical  purposes,  as  follows: 
First,  we prepare  human  plasma  from  a  normal  case  just  as  we 
prepared  the oxalated plasma  which is to be tested.  Five  drops of 
this plasma are put into five thoroughly cleansed vials.  The first of 
these serves  as a  control; to the second three drops of normal  anti- 
thrombin are added; to the third five drops of normal antithrombin; 
to  the  fourth three  drops  of  the  antithrombin  that  is  to be  tested; 
and to the fifth five drops of this antithrombin.  All tubes are equal- 
ized  in  amount  by  the  addition  of  normal  salt  solution,  and  the 
mixtures are allowed to remain in contact for fifteen minutes.  The 
plasma  is  then  recalcified  by  the  addition  of  0. 5  per  cent.  calcium 
chloride,  the  number  of  drops  which are  added  having  been deter- 
mined by the general coagulability test, which should always precede 
the  antithrombin  test.  As  a  rule,  four  drops  have  been  found  to 
be the optimal amount. 
TABLE  I. 
Antithrombin  Test. 
A. 
Control. 
+ 
+++ 
Normal.  Hemophilia. 
Interval. 
3 drops 
antithrombin. 
m 
+ 
+++ 
5 drops 
antithrombin. 
m 
+ 
++ 
+++ 
3 drops  5 drops 
antithrombin,  antithrombin. 
+  + 
+++  ++ 
+++ 
2  min. 
4  rain. 
6  min. 
8  rain. 
B. 
Normal.  Pul  tara. 
Control. 
+ 
+ 
+++ 
3 drops 
antithrombin. 
+ 
+ 
++ 
+++ 
5 drops 
antithrombin. 
+ 
q- 
++ 
++ 
++ 
+++ 
3drops 
antithrombin. 
+ 
q- 
+ 
++ 
+++ 
5 drops 
antithrombin. 
m 
+ 
+ 
+ 
++ 
++ 
+++ 
Interval. 
4  min. 
6  min. 
8  rain. 
I0  min. 
i2  min. 
I4 rain. 
I6  rain. 
Table 1.4 illustrates a test of this kind in an atypical case of hemo- 
philia  where  there  was  a  deficiency  of  calcium  in  the  blood.  We 
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greater degree than in the normal plasma; in both instances coagula- 
tion was rapid and but slightly delayed by the addition of three and 
of five drops  of antithrombin.  Table I  B  illustrates a  similar test 
in  a  case  of purpura.  Here we likewise find no increase  in  anti- 
thrombin. 
Antithrombin  is  judged  to  be  in  excess  where a  marked  delay 
in  coagulation is  brought  about  in  the tubes  to  which it  has  been 
added, as compared with the coagulation in the control tube.  As in 
the case of the coagulation time, no arbitrary norm can be set up; 
the results should be well defined to warrant the conclusion that there 
is an excess of antithrombin. 
The essential difference between this antithrombin test and that of 
Howell is that plasma is used as a 'basis  instead of a fibrinogen solu- 
tion.  The validity of employing plasma in this way may be deter- 
mined by preparing solutions  of hirudin  of varying strengths  and 
titrating them upon plasma; in other words, by substituting hirudin 
for  human  antithrombin.  Tests  of  this  nature  were  carried  out, 
first upon horse plasma, and later upon normal human plasma.  In 
both cases the plasma was clear and had a  coagulation time of not 
over ten minutes.  Table II A  illustrates an experiment of this kind. 
We may note that  dilutions  of  I  to 20,000,  30,000,  and 40,000  of 
hirudin were employed, and that in each instance I,  3,  and 5  drops 
of  one  of  these  antithrombin  solutions  were  added  to  the  human 
plasma.  It will be seen that in each of the three tests the sequence 
of coagulation is in direct ratio to the number of drops of antithrom- 
bin added, and that in general the more dilute the hirudin, the less 
its  inhibiting  effect.  A  test  (table  II  B)  of  normal  human  an.ti- 
thrombin upon its own plasma has been added to this table to enable 
a comparison between the strengths of the hirudin used and of human 
antithrombin.  It will be seen that, according to the test, human anti- 
thrombin is about equal to a  I  to 40,000 solution of hirudin. 
If we turn again to table I, we notice that in addition to the tests 
of  plasma  in  the  case  of  purpura  and  of  hemophilia,  it  includes 
titrations  of  antithrombin  upon  autogenous  plasma.  In  these  in- 
stances the plasma was normal.  The same autogenous test may be 
carried out in pathological cases; e.  g.,  in hemophilia, as shown in 
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same plasma which is  reported in table  I.  This  test evidently can 
not be considered an antithrombin test, as  we employ plasma  from 
a pathological case in order to ascertain the degree of antithrombin. 
It is termed an equilibrium test because it gives us information as to 
the  balance  which obtains  in  the  plasma  between all  positive  and 
negative  factors  concerned in  coagulation.  If  the  balance  is  in  a 
state  of  delicate  adjustment,  the  addition  of  a  small  amount  of 
antithrombin  will  suffice greatly  to  delay  coagulation,  whereas  if 
there is  an excess of prothrombin and allied substances,  this  addi- 
tion  will bring about but a  slight increase in the coagulation time. 
We see this when we compare the two tables.  In table I, where two 
equilibrium tests of normal plasma are shown, the addition of three 
drops of antithrombin resulted in either slight or no delay, and five 
drops brought  about  at most a  retardation  of  from ten to  sixteen 
minutes.  These tests must not be considered exceptions to the rule, 
although the delay when three drops  of antithrombin are added is 
generally more'marked, and when five drops are added, the period 
of complete coagulation is  postponed to  fifteen or twenty minutes. 
On the other hand, with the plasma of the hemophiliac, referred to 
in  table  I,  the addition of the same amounts of antithrombin  was 
sufficient to retard coagulation markedly (table III).  Comparative 
tests such as these demonstrate that the mere coagulation time does 
not furnish complete information as regards the power for clotting 
which  exists  in  plasma.  There  are latent  potential  coagulative 
factors  which  come  to  light  only  when  inhibiting  substances  are 
added to the plasma.  For example, a  normal plasma  (table II A) 
coagulated in ten minutes; the plasma of the hemophiliac (table III) 
in twelve minutes, that is,  almost in the same length of time; never- 
theless, upon the addition of five drops of its own antithrombin, the 
former coagulated in sixteen minutes, whereas the latter took forty- 
three  minutes  to  clot.  This  test  is  not  recommended for  clinical 
use,  because the testing of antithrombin  upon  abnormal  plasma  is 
erroneous.  However,  it  is  highly  significant  from  one  point  of 
view : it shows that the circulating blood is not delicately balanced in 
regard to  its  coagulability.  When we  reflect that  in  adding three 
and five drops of antithrombin to five drops of plasma we are more 
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theless  coagulation  generally  ensues  with  but slight  retardation,  we 
must  conclude  that  there  exists  a  considerable  factor  of  safety  in 
the mechanism  of the coagulation of the  circulating blood.  If such 
were not the case,  serious hemorrhage,  as the result  of a  slight tem- 
porary excess of antithrombin,  would be a  constant danger. 
TABLE II. 
A. Hirudln. 
Dilution  1:2o,ooo. 
x drop  hirudin.  3drops  hirudin.  5 drops hlntdin.  Interval. 
+ 
++ 
++ 
++ 
+++ 
+ 
+ 
++ 
++ 
++ 
++ 
+++ 
+ 
+ 
+ 
++ 
++ 
++ 
++ 
+++ 
5  min. 
8  min. 
Xo min. 
II  min. 
12  rain. 
14 rain. 
16 min. 
I8  min. 
20 min. 
22  min. 
Dilution  I : 30,000. 
x drop hirudin.  3 drops hiradin.  5 drops hirudin.  Interval. 
+ 
++ 
+++ 
+ 
++ 
++ 
++ 
+++ 
+ 
+ 
++ 
++ 
++ 
+++ 
5  min. 
8  min. 
I0 min. 
I I  min. 
12  min. 
i4 min. 
16  min. 
Dilution  I : 4o,ooo. 
t drop hirudin.  3 drops hlrudin.  5 drops hlrudin.  Interval. 
+ 
+++ 
+ 
++ 
++ 
++ 
+++ 
+ 
++ 
++ 
++ 
++ 
+++ 
5  min. 
8  min. 
io  min. 
i i  min. 
I2  min. 
14 min. 
16 min. 
B.  Antithrombin  Test. 
Control. 
+ 
++ 
+++ 
x drop antithrombin. 
+ 
++ 
+++ 
3 drops antithrombin.  5 drops antithrombin. 
+  +  ++ 
+++  +++++++  ++ 
nterval. 
5 min. 
8 min. 
io min. 
I I rain. 
12 min. 
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TABLE III. 
Equilibrium  Test.  1 
I 
Control.  3 drops antithrombin.  /  5  drops antithrombin.  Interval 
--  --  [  --  6  min. 
+  +  +  Io min. 
+q-q-  "-b  +  I2 rain. 
-k-b+  +  ~5 min. 
-t- q-  35 min. 
"}- q- -b  43 min. 
SUMMARY. 
A test is described for the estimation of antithrombin in the blood. 
The chief advantage of the test is that it is simple, and does not re- 
quire  the  preparation  of  fibrinogen  and  of  thrombin,  which  are 
difficult to prepare and to maintain in a  pure state.  The principle 
consists in titrating the antithrombin against normal human plasma; 
in this way we obtain an estimation of its power to delay coagula- 
tion.  As the result of examinations carried out by this method, it 
would  seem  that  there  is  a  wide  factor  of  safety  as  regards  the 
amount of antithrombin in the human blood, and that this inhibiting 
substance may be increased to a  considerable degree without mark- 
edly delaying or endangering clotting. 
1 The  same  case  as  in  table  I  .4. 